Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Alison C. Johnson, Margarida Matias, Helen Boyle, Bernard Escudier, Alicia Molinier, Brigitte Laguerre, Carole Helissey, Pierre-Emmanuel Brachet, Audrey Emmanuelle Dugué, Loic Mourey, Elodie Coquan, Florence Joly

ABSTRACT

BACKGROUND: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. METHODS: Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment. RESULTS: Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62 years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8 months. During the first three months, the median increase of HbL was +2.3 g/dL (-1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P < 0.0001) and gender (P = 0.0041), the combination of HbL increase ≥2.3 g/dL and any grade hBP was significantly associated with longer PFS (HR = 0.40, 95%CI [0.24; 0.68]). CONCLUSIONS: Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting. More... »

PAGES

355

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-017-3312-7

DOI

http://dx.doi.org/10.1186/s12885-017-3312-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085558684

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28532444


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemoglobins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polycythemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Alison C.", 
        "id": "sg:person.011070530545.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011070530545.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, F-94800, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matias", 
        "givenName": "Margarida", 
        "id": "sg:person.011632077231.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011632077231.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on B\u00e9rard, F-69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyle", 
        "givenName": "Helen", 
        "id": "sg:person.0616261742.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Institut Gustave Roussy, F-94800, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Claudius Regaud", 
          "id": "https://www.grid.ac/institutes/grid.417829.1", 
          "name": [
            "Institut Claudius Regaud, F-31000, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molinier", 
        "givenName": "Alicia", 
        "id": "sg:person.014634071077.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014634071077.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Eug\u00e8ne Marquis", 
          "id": "https://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Centre Eug\u00e8ne Marquis, F-35000, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laguerre", 
        "givenName": "Brigitte", 
        "id": "sg:person.01171673663.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171673663.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital d'instruction des Arm\u00e9es B\u00e9gin", 
          "id": "https://www.grid.ac/institutes/grid.414007.6", 
          "name": [
            "HIA B\u00e9gin, F-94160, Saint-Mand\u00e9, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Helissey", 
        "givenName": "Carole", 
        "id": "sg:person.01301564511.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301564511.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brachet", 
        "givenName": "Pierre-Emmanuel", 
        "id": "sg:person.012041777677.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012041777677.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dugu\u00e9", 
        "givenName": "Audrey Emmanuelle", 
        "id": "sg:person.0744145733.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744145733.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Claudius Regaud", 
          "id": "https://www.grid.ac/institutes/grid.417829.1", 
          "name": [
            "Institut Claudius Regaud, F-31000, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mourey", 
        "givenName": "Loic", 
        "id": "sg:person.0634766027.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634766027.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coquan", 
        "givenName": "Elodie", 
        "id": "sg:person.01116704511.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116704511.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Franois Baclesse", 
          "id": "https://www.grid.ac/institutes/grid.476192.f", 
          "name": [
            "Centre Fran\u00e7ois Baclesse, F-14000, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joly", 
        "givenName": "Florence", 
        "id": "sg:person.01130240530.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130240530.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2008.21.4809", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003290766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07357900902744528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013444091"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1428", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015883708", 
          "https://doi.org/10.1038/nm1428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1428", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015883708", 
          "https://doi.org/10.1038/nm1428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-04-083501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019515821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2015.07.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020012153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2013-0006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021108848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2013.236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021784090", 
          "https://doi.org/10.1038/bjc.2013.236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semcancer.2012.06.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025479081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.6151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027642326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1087", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028715249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030831573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71222-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032250619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2011.06.049", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032436422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0652", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040763592"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.18.3525", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052780841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078205324", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis.\nMETHODS: Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment.\nRESULTS: Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62\u00a0years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8\u00a0months. During the first three months, the median increase of HbL was +2.3\u00a0g/dL (-1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P\u00a0<\u00a00.0001) and gender (P\u00a0=\u00a00.0041), the combination of HbL increase \u22652.3\u00a0g/dL and any grade hBP was significantly associated with longer PFS (HR\u00a0=\u00a00.40, 95%CI [0.24; 0.68]).\nCONCLUSIONS: Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-017-3312-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study", 
    "pagination": "355", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "24398f3b8247988f7f18f74a9a79b527b3f540dd7870d85afc164bbd0bb75d2a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28532444"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-017-3312-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085558684"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-017-3312-7", 
      "https://app.dimensions.ai/details/publication/pub.1085558684"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89793_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-017-3312-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3312-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3312-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3312-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-017-3312-7'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      69 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-017-3312-7 schema:about N022211cf644d47e1a130665fa2c317aa
2 N04af456d065d46d2ba4f080e5dd0a17a
3 N084a83917f8041688299f3b48a5842a4
4 N09906e12b33c4169b6b0eb429b2c4518
5 N09aef093e5b947a99cc22009e4032371
6 N0dc63f1d4879497fa5b6fd713ab661d5
7 N143db79b2df5446e8ca6bcd55607d0c7
8 N1a68f4f910184f63a0e5ee3dfc838b70
9 N4230760401584377bac82b983d4ea49f
10 N4663931f23654951bd6bf979bb76f7f1
11 N96f84da0537846b284f8e52135d70fd8
12 N971881cbea054cb0b41c56cd50009cc0
13 N9c60e358a0cd45968b1fb2700ef5b2d1
14 Na0a215bf714f43fda29c315a2b8bc913
15 Na748cbe823d042a4a2bb8f98cf596af5
16 Nae16861ff14a47e68ac66d77133d8782
17 Naf1f155d22de440d866f68a6cc4f5b0d
18 Nb2ee524be42e4f27b93767d42b426158
19 Nb3fab3e6e6b64861b84b18aa1170584d
20 Ne6fa0d4d19294c8caa5b3c1ccfa55d19
21 Neb1db7ba8bb3434bb3147df4ba8a1048
22 Nf47f6e5ca62b480b8931f95ec0de19e7
23 Nfd17e69abe0a44ba85b913aa9049ae86
24 anzsrc-for:11
25 anzsrc-for:1103
26 schema:author Nb0c1f6dc35c94973809dddfc9c5c656a
27 schema:citation sg:pub.10.1038/bjc.2013.236
28 sg:pub.10.1038/nm1428
29 https://app.dimensions.ai/details/publication/pub.1078205324
30 https://doi.org/10.1016/j.clgc.2015.07.003
31 https://doi.org/10.1016/j.eururo.2011.06.049
32 https://doi.org/10.1016/j.semcancer.2012.06.001
33 https://doi.org/10.1016/s0140-6736(11)61613-9
34 https://doi.org/10.1016/s1470-2045(14)71222-7
35 https://doi.org/10.1080/07357900902744528
36 https://doi.org/10.1158/1078-0432.ccr-08-0652
37 https://doi.org/10.1158/1078-0432.ccr-10-2806
38 https://doi.org/10.1182/blood-2007-04-083501
39 https://doi.org/10.1200/jco.2008.18.3525
40 https://doi.org/10.1200/jco.2008.20.1087
41 https://doi.org/10.1200/jco.2008.20.6151
42 https://doi.org/10.1200/jco.2008.21.4809
43 https://doi.org/10.1634/theoncologist.2013-0006
44 schema:datePublished 2017-12
45 schema:datePublishedReg 2017-12-01
46 schema:description BACKGROUND: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. METHODS: Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment. RESULTS: Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62 years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8 months. During the first three months, the median increase of HbL was +2.3 g/dL (-1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P < 0.0001) and gender (P = 0.0041), the combination of HbL increase ≥2.3 g/dL and any grade hBP was significantly associated with longer PFS (HR = 0.40, 95%CI [0.24; 0.68]). CONCLUSIONS: Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree true
50 schema:isPartOf N23b87031f00848fc92d850cebb575351
51 Nc91e079796994947b9cda91fd4dbddb9
52 sg:journal.1024632
53 schema:name Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
54 schema:pagination 355
55 schema:productId N2fcc8435987a43c3b03a850df0a43b60
56 N95ce36a851564418b4681e90f0d24d2a
57 Nabb21b06f466447d908973ef7e43ac1e
58 Nbe533e3de29a4ad09d035d54cdd804b2
59 Ndf91a82118624d9da5fb26ca5d77ac09
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085558684
61 https://doi.org/10.1186/s12885-017-3312-7
62 schema:sdDatePublished 2019-04-11T09:53
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher N0f9b573e92e64656a13e776b6f79c982
65 schema:url https://link.springer.com/10.1186%2Fs12885-017-3312-7
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N022211cf644d47e1a130665fa2c317aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Indazoles
71 rdf:type schema:DefinedTerm
72 N04af456d065d46d2ba4f080e5dd0a17a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Biomarkers, Tumor
74 rdf:type schema:DefinedTerm
75 N084a83917f8041688299f3b48a5842a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Male
77 rdf:type schema:DefinedTerm
78 N09906e12b33c4169b6b0eb429b2c4518 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Antineoplastic Agents
80 rdf:type schema:DefinedTerm
81 N09aef093e5b947a99cc22009e4032371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Kaplan-Meier Estimate
83 rdf:type schema:DefinedTerm
84 N0dc63f1d4879497fa5b6fd713ab661d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Middle Aged
86 rdf:type schema:DefinedTerm
87 N0f9b573e92e64656a13e776b6f79c982 schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 N143db79b2df5446e8ca6bcd55607d0c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Imidazoles
91 rdf:type schema:DefinedTerm
92 N1a68f4f910184f63a0e5ee3dfc838b70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Treatment Outcome
94 rdf:type schema:DefinedTerm
95 N23b87031f00848fc92d850cebb575351 schema:issueNumber 1
96 rdf:type schema:PublicationIssue
97 N2fcc8435987a43c3b03a850df0a43b60 schema:name pubmed_id
98 schema:value 28532444
99 rdf:type schema:PropertyValue
100 N4230760401584377bac82b983d4ea49f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Kidney Neoplasms
102 rdf:type schema:DefinedTerm
103 N4663931f23654951bd6bf979bb76f7f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Hemoglobins
105 rdf:type schema:DefinedTerm
106 N549a26ecf2bb44e7a91de658dc69b08f rdf:first sg:person.0616261742.66
107 rdf:rest Nfa3ded9c12674336bbc2216e6a40a0b2
108 N65e2c95f3ef847feaa831641cfd1b86d rdf:first sg:person.01171673663.25
109 rdf:rest N82b7236e063b4657bf9de94b43bbcaa1
110 N6bbc5b00533948c7b9d13a70a999047d rdf:first sg:person.012041777677.81
111 rdf:rest N9ac60396c5b94c1fb3af0f4b90ae4226
112 N7a0938ef52064c2889ae80212b833616 rdf:first sg:person.011632077231.49
113 rdf:rest N549a26ecf2bb44e7a91de658dc69b08f
114 N7e55dd800eac40bbbb85092fe5718111 rdf:first sg:person.01130240530.48
115 rdf:rest rdf:nil
116 N82b7236e063b4657bf9de94b43bbcaa1 rdf:first sg:person.01301564511.14
117 rdf:rest N6bbc5b00533948c7b9d13a70a999047d
118 N87d524e12376492d92813fd78bb8d3ab rdf:first sg:person.01116704511.65
119 rdf:rest N7e55dd800eac40bbbb85092fe5718111
120 N95ce36a851564418b4681e90f0d24d2a schema:name nlm_unique_id
121 schema:value 100967800
122 rdf:type schema:PropertyValue
123 N96f84da0537846b284f8e52135d70fd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Carcinoma, Renal Cell
125 rdf:type schema:DefinedTerm
126 N971881cbea054cb0b41c56cd50009cc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Young Adult
128 rdf:type schema:DefinedTerm
129 N9ac60396c5b94c1fb3af0f4b90ae4226 rdf:first sg:person.0744145733.83
130 rdf:rest Nc162cd6c24f141e8927048dad7490d12
131 N9c60e358a0cd45968b1fb2700ef5b2d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged, 80 and over
133 rdf:type schema:DefinedTerm
134 Na0a215bf714f43fda29c315a2b8bc913 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 Na748cbe823d042a4a2bb8f98cf596af5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Adult
139 rdf:type schema:DefinedTerm
140 Nabb21b06f466447d908973ef7e43ac1e schema:name doi
141 schema:value 10.1186/s12885-017-3312-7
142 rdf:type schema:PropertyValue
143 Nae16861ff14a47e68ac66d77133d8782 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged
145 rdf:type schema:DefinedTerm
146 Naf1f155d22de440d866f68a6cc4f5b0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Nb0c1f6dc35c94973809dddfc9c5c656a rdf:first sg:person.011070530545.08
150 rdf:rest N7a0938ef52064c2889ae80212b833616
151 Nb2ee524be42e4f27b93767d42b426158 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Proportional Hazards Models
153 rdf:type schema:DefinedTerm
154 Nb3fab3e6e6b64861b84b18aa1170584d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Disease-Free Survival
156 rdf:type schema:DefinedTerm
157 Nbe533e3de29a4ad09d035d54cdd804b2 schema:name dimensions_id
158 schema:value pub.1085558684
159 rdf:type schema:PropertyValue
160 Nc162cd6c24f141e8927048dad7490d12 rdf:first sg:person.0634766027.00
161 rdf:rest N87d524e12376492d92813fd78bb8d3ab
162 Nc91e079796994947b9cda91fd4dbddb9 schema:volumeNumber 17
163 rdf:type schema:PublicationVolume
164 Ndf91a82118624d9da5fb26ca5d77ac09 schema:name readcube_id
165 schema:value 24398f3b8247988f7f18f74a9a79b527b3f540dd7870d85afc164bbd0bb75d2a
166 rdf:type schema:PropertyValue
167 Ne6fa0d4d19294c8caa5b3c1ccfa55d19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Multivariate Analysis
169 rdf:type schema:DefinedTerm
170 Neb1db7ba8bb3434bb3147df4ba8a1048 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Axitinib
172 rdf:type schema:DefinedTerm
173 Nf472ff0ea46e4ea8880c96b9aa84f83c rdf:first sg:person.014634071077.02
174 rdf:rest N65e2c95f3ef847feaa831641cfd1b86d
175 Nf47f6e5ca62b480b8931f95ec0de19e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Polycythemia
177 rdf:type schema:DefinedTerm
178 Nfa3ded9c12674336bbc2216e6a40a0b2 rdf:first sg:person.01304252172.82
179 rdf:rest Nf472ff0ea46e4ea8880c96b9aa84f83c
180 Nfd17e69abe0a44ba85b913aa9049ae86 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Retrospective Studies
182 rdf:type schema:DefinedTerm
183 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
184 schema:name Medical and Health Sciences
185 rdf:type schema:DefinedTerm
186 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
187 schema:name Clinical Sciences
188 rdf:type schema:DefinedTerm
189 sg:journal.1024632 schema:issn 1471-2407
190 schema:name BMC Cancer
191 rdf:type schema:Periodical
192 sg:person.011070530545.08 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
193 schema:familyName Johnson
194 schema:givenName Alison C.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011070530545.08
196 rdf:type schema:Person
197 sg:person.01116704511.65 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
198 schema:familyName Coquan
199 schema:givenName Elodie
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116704511.65
201 rdf:type schema:Person
202 sg:person.01130240530.48 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
203 schema:familyName Joly
204 schema:givenName Florence
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130240530.48
206 rdf:type schema:Person
207 sg:person.011632077231.49 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
208 schema:familyName Matias
209 schema:givenName Margarida
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011632077231.49
211 rdf:type schema:Person
212 sg:person.01171673663.25 schema:affiliation https://www.grid.ac/institutes/grid.417988.b
213 schema:familyName Laguerre
214 schema:givenName Brigitte
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171673663.25
216 rdf:type schema:Person
217 sg:person.012041777677.81 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
218 schema:familyName Brachet
219 schema:givenName Pierre-Emmanuel
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012041777677.81
221 rdf:type schema:Person
222 sg:person.01301564511.14 schema:affiliation https://www.grid.ac/institutes/grid.414007.6
223 schema:familyName Helissey
224 schema:givenName Carole
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301564511.14
226 rdf:type schema:Person
227 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
228 schema:familyName Escudier
229 schema:givenName Bernard
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
231 rdf:type schema:Person
232 sg:person.014634071077.02 schema:affiliation https://www.grid.ac/institutes/grid.417829.1
233 schema:familyName Molinier
234 schema:givenName Alicia
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014634071077.02
236 rdf:type schema:Person
237 sg:person.0616261742.66 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
238 schema:familyName Boyle
239 schema:givenName Helen
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616261742.66
241 rdf:type schema:Person
242 sg:person.0634766027.00 schema:affiliation https://www.grid.ac/institutes/grid.417829.1
243 schema:familyName Mourey
244 schema:givenName Loic
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634766027.00
246 rdf:type schema:Person
247 sg:person.0744145733.83 schema:affiliation https://www.grid.ac/institutes/grid.476192.f
248 schema:familyName Dugué
249 schema:givenName Audrey Emmanuelle
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744145733.83
251 rdf:type schema:Person
252 sg:pub.10.1038/bjc.2013.236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021784090
253 https://doi.org/10.1038/bjc.2013.236
254 rdf:type schema:CreativeWork
255 sg:pub.10.1038/nm1428 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015883708
256 https://doi.org/10.1038/nm1428
257 rdf:type schema:CreativeWork
258 https://app.dimensions.ai/details/publication/pub.1078205324 schema:CreativeWork
259 https://doi.org/10.1016/j.clgc.2015.07.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020012153
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/j.eururo.2011.06.049 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032436422
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1016/j.semcancer.2012.06.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025479081
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s1470-2045(14)71222-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032250619
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1080/07357900902744528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013444091
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1158/1078-0432.ccr-08-0652 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040763592
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1158/1078-0432.ccr-10-2806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030831573
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1182/blood-2007-04-083501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019515821
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.2008.18.3525 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052780841
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2008.20.1087 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028715249
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2008.20.6151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027642326
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1200/jco.2008.21.4809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003290766
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1634/theoncologist.2013-0006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021108848
286 rdf:type schema:CreativeWork
287 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
288 schema:name Institut Gustave Roussy, F-94800, Villejuif, France
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.414007.6 schema:alternateName Hôpital d'instruction des Armées Bégin
291 schema:name HIA Bégin, F-94160, Saint-Mandé, France
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.417829.1 schema:alternateName Institut Claudius Regaud
294 schema:name Institut Claudius Regaud, F-31000, Toulouse, France
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.417988.b schema:alternateName Centre Eugène Marquis
297 schema:name Centre Eugène Marquis, F-35000, Rennes, France
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
300 schema:name Centre Léon Bérard, F-69008, Lyon, France
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.476192.f schema:alternateName Centre Franois Baclesse
303 schema:name Centre François Baclesse, F-14000, Caen, France
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...